For the patient subgroup without actionable mutations, guidelines recommend first-line ICB monotherapy for patients with high programmed death-ligand 1 (PD-L1) tumor proportion scores (TPS) (≥50%) or chemoimmunotherapy regimens irrespective of PD-L1 expression.2 This evidence concerns the gene CD274 and neoplasm.